Phase II trial of saracatinib (AZD0530), an oral src-inhibitor for the treatment of patients with hormone receptor negative metastatic breast cancer

BACKGROUND: Src activation is associated with cell migration, proliferation and metastasis. Saracatinib is an oral, tyrosine kinase inhibitor (TKI) selective for Src. We performed this trial to evaluate the efficacy and safety of saracatinib monotherapy in patients with estrogen receptor (ER)- and p...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Gucalp, Ayca, Sparano, Joseph A., Caravelli, James, Santamauro, Jean, Patil, Sujata, Abbruzzi, Alyson, Pellegrino, Christine, Bromberg, Jackie, Dang, Chau, Theodoulou, Maria, Massague, Joan, Norton, Larry, Hudis, Clifford, Traina, Tiffany A.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2011
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3222913/
https://ncbi.nlm.nih.gov/pubmed/21729667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clbc.2011.03.021
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares